IDH2 and acute myeloid leukemia: As for IDH2 mutations, enasidenib was FDA-approved in 2017 for relapsed/refractory AML patients, and a phase III trial (NCT02577406) comparing enasidenib to conventional care regimens respectively showed improved event-free survival (4.9 vs. 2.6 months) and overall response rate (40.5% vs. 9.9%), although the study did not indicate improved overall survival [98].